Oral pharmaceutical composition of isotretinoin

Patent metadata

Field	Value
Publication number	US-2016346241-A1
Application number	US-201514958532-A
Country	US
Kind code	A1
Filing date	Dec 3, 2015
Priority date	May 29, 2015
Publication date	Dec 1, 2016
Grant date	—

Abstract

The present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.

First claim

1 . An oral pharmaceutical composition of isotretinoin having enhanced bioavailability wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix.

2 . The oral pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable matrix is a polymeric matrix, a non-polymeric matrix, or a combination thereof.

3 . The oral pharmaceutical composition according to claim 2 , wherein the polymeric matrix is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, carboxymethyl cellulose calcium, polyvinylpyrrolidone, polyethylene oxide, polyvinyl alcohol, methyl cellulose, ethyl cellulose, propyl cellulose, ethylmethyl cellulose, isopropyl cellulose, ethylpropyl cellulose, butyl cellulose, benzyl cellulose, cellulose esters, cellulose cyanoalkyl ethers, methacrylic acid-acrylic acid copolymers, methacrylic acid copolymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, and mixtures thereof.

4 . The oral pharmaceutical composition according to claim 2 , wherein the non-polymeric matrix is selected from the group consisting of sugars, sugar alcohols, cyclodextrin, polyethylene glycol, polyethylene glycol esters, medium chain triglycerides, fatty acids, fatty alcohols, waxes, fatty acid esters, polyoxyethylene sorbitan fatty acid esters, urea, and mixtures thereof.

5 . The oral pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable matrix is present in an amount of about 1% w/w to about 90% w/w by total weight of the composition.

6 . The oral pharmaceutical composition according to claim 5 , wherein the pharmaceutically acceptable matrix is present in an amount of about 50% w/w to about 85% w/w by total weight of the composition.

7 . The oral pharmaceutical composition according to claim 1 , wherein said composition comprises isotretinoin in an amount of about 1 mg to 100 mg, 5 mg to 50 mg, 10 mg to 40 mg, 9 mg to 36 mg, or 8 mg to 32 mg.

8 . The oral pharmaceutical composition according to claim 7 , wherein said composition comprises isotretinoin in an amount of about 40 mg.

9 . The oral pharmaceutical composition according to claim 7 , wherein said composition comprises isotretinoin in an amount of about 32 mg, 28 mg, 24 mg, 20 mg, 16 mg, or 8 mg.

10 . (canceled)

11 . The oral pharmaceutical composition according to claim 1 , wherein said composition is in the form of a solid dosage form comprising a solid dispersion of isotretinoin and a pharmaceutically acceptable matrix.

12 . The oral pharmaceutical composition according to claim 1 , wherein said composition further comprises one or more pharmaceutically acceptable excipients selected from the group comprising binders, disintegrants, fillers, lubricants, glidants, surfactants, stabilizing agents, colors, flavors, preservatives, and combinations thereof.

13 . The oral pharmaceutical composition according to claim 1 , wherein said composition is stable when stored at 40° C. and 75% relative humidity or at 25° C. and 60% relative humidity for a period of at least three months.

14 . A process for preparing the oral pharmaceutical composition of claim 1 , wherein said process is solvent evaporation method, melting method, kneading method, co-grinding method, co-precipitation method, freeze-drying, coating, or adsorbing the drug onto carrier particles.

15 . The process according to claim 14 , wherein said process comprises:
a) dissolving isotretinoin and a pharmaceutically acceptable matrix in a solvent; and b) evaporating the solvent to form a solid dispersion of isotretinoin.

16 . The process according to claim 14 , wherein said process comprises:
a) dissolving isotretinoin and one or more excipients in a solvent; b) coating or adsorbing the solution of step a) onto a pharmaceutically acceptable matrix to form solid particles or granules; and c) filling the solid particles or granules of step b) into capsules or compressing into tablets with one or more pharmaceutically acceptable excipients.

17 . The oral pharmaceutical composition according to claim 1 , wherein said composition, when administered orally, provides equivalent efficacy at a lower dose of isotretinoin in comparison to the marketed Absorica® capsules, wherein said dose is at least 10% lower.

18 . The oral pharmaceutical composition according to claim 1 , wherein said composition, when administered orally, provides equivalent efficacy at a lower dose of isotretinoin in comparison to the marketed Absorica® capsules, wherein said dose is at least 20% lower.

19 . The oral pharmaceutical composition according to claim 1 , wherein said composition exhibits reduced food effect as indicated by comparable C max and AUC in fasting and fed states.

20 . The oral pharmaceutical composition according to claim 1 , wherein said composition is used for the treatment of acne, musculoskeletal and connective tissue inflammations, emphysema, ulcerating diseases, cervical tumors in HIV positive women, lung cancer in smokers, skin cancer, neuroblastoma, recurrent prostate cancer, leukemia, high-grade glioma, head and neck cancers, multiple myeloma, gram-negative folliculitis, recalcitrant rosacea, pyoderma faciale, psoriasis, cutaneous lupus erythematosus, acne fulminans, squamous cell carcinoma, or cutaneous photoaging.

21 . The oral pharmaceutical composition according to claim 20 , wherein said composition is used for the treatment of acne.

22 . A method of treating acne, musculoskeletal and connective tissue inflammations, emphysema, ulcerating diseases, cervical tumors in HIV positive women, lung cancer in smokers, skin cancer, neuroblastoma, recurrent prostate cancer, leukemia, high-grade glioma, head and neck cancers, multiple myeloma, gram-negative folliculitis, recalcitrant rosacea, pyoderma faciale, psoriasis, cutaneous lupus erythematosus, acne fulminans, squamous cell carcinoma, or cutaneous photoaging comprising administering to a patient in a need thereof a therapeutically effective amount of the oral pharmaceutical composition of claim 1 .

23 . The method according to claim 22 , wherein the patient has acne.

24 . The oral composition according to claim 1 , wherein said composition releases more than 50% of isotretinoin in 15 minutes in a media with a pH of 10.5.

Assignees

• Sun Pharmaceutical Ind Ltd

Inventors

• AMRUTKAR Pankaj Prabhakar
• Madan Sumit
• Kochhar Ravi
• Deshmukh Subodh

Classifications

• A61K9/4833

  Encapsulating processes; Filling of capsules (mechanical aspects A61J3/07) · CPC title

• B29C43/006

  Pressing and sintering powders, granules or fibres · CPC title

• A61J3/07

  into the form of capsules or similar small containers for oral use · CPC title

• A61K31/203 Primary

  Retinoic acids {; Salts thereof} · CPC title

• B29L2031/753

  Medical equipment; Accessories therefor (bloodbags, medical bags B29L2031/7148; artificial eyes B29L2011/0008) · CPC title